Functional Genetics Announces Discovery of Target That Regulates Alzheimer's Disease

Gaithersburg, MD, November 14, 2009 --( Investigators at Functional Genetics, working with scientists at the Burnham Institute for Medical Research, Stanford University and Rockefeller University, have utilized its proprietary RHGP discovery technology to identify a novel gene (Rps23r1) in mice that reduces the accumulation of two toxic proteins that are major players in Alzheimer's disease: amyloid beta and tau.

Amyloid beta is responsible for the lesions found in the brains of Alzheimer's patients. Tau causes the tangles that typify the disease in patients' brain cells. The study was published in the journal, Neuron, on November 12.

These findings could lead to new treatments for Alzheimer's disease. “We are also pleased to announce that we have recently identified the corresponding gene in human and hope that this work can help in the fight to treat Alzheimer's Disease,” said Dr. Michael Kinch, Vice President of Research and Development at Functional Genetics. “The work conducted by Drs. Wu-Bo Li and Limin Li at Functional Genetics, provides new insight into mechanisms governing disease causation and potential treatments”, added Dr. Michael Goldblatt, President and CEO of Functional Genetics.”

About Functional Genetics, Inc.

Functional Genetics, Inc. (FGI) is a privately-held, development stage biotechnology company, headquartered in Gaithersburg, MD. We use innovative host-oriented science to develop better medicines to treat or prevent infectious diseases and cancer. Our unique scientific approaches have allowed us to develop novel antiviral drugs that demonstrate beneficial activity against a broad-spectrum of different viruses, including HIV, RSV, Influenza, HBV, HCV and bio-threat pathogens, such as Ebola.
For more information, visit Functional Genetics’ website at

Functional Genetics, Inc.
Phone: +1.240.631.6790

Functional Genetics, Inc.
Michael Kinch